{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:40Z","timestamp":1787017060481,"version":"build-2736575974"},"reference-count":99,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030110"],"award-info":[{"award-number":["82030110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104166"],"award-info":[{"award-number":["82104166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330117"],"award-info":[{"award-number":["82330117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,12,26]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>The use of biologics in various diseases has dramatically increased in recent years. Stroke, a cerebrovascular disease, is the second most common cause of death, and the leading cause of disability with high morbidity worldwide. For biologics applied in the treatment of acute ischaemic stroke, alteplase is the only thrombolytic agent. Meanwhile, current clinical trials show that two recombinant proteins, tenecteplase and non-immunogenic staphylokinase, are most promising as new thrombolytic agents for acute ischaemic stroke therapy. In addition, stem cell-based therapy, which uses stem cells or organoids for stroke treatment, has shown promising results in preclinical and early clinical studies. These strategies for acute ischaemic stroke mainly rely on the unique properties of undifferentiated cells to facilitate tissue repair and regeneration. However, there is a still considerable journey ahead before these approaches become routine clinical use. This includes optimising cell delivery methods, determining the ideal cell type and dosage, and addressing long-term safety concerns. This review introduces the current or promising recombinant proteins for thrombolysis therapy in ischaemic stroke and highlights the promise and challenges of stem cells and cerebral organoids in stroke therapy.<\/jats:p>","DOI":"10.1136\/svn-2023-002883","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T10:45:42Z","timestamp":1706525142000},"page":"467-480","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-stroke biologics: from recombinant proteins to stem cells and organoids"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01287936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02448641","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01151124","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02117635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03541668","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zhu-Wei","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Second Military Medical University\/ Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Second Military Medical University\/ Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Li","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Second Military Medical University\/ Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Second Military Medical University\/ Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-3434","authenticated-orcid":false,"given":"Chao-Yu","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Second Military Medical University\/ Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2025082410350821000_9.5.467.1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.tips.2015.08.012","article-title":"NAMPT as a therapeutic target against stroke","volume":"36","author":"Wang","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"2025082410350821000_9.5.467.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30962-X"},{"key":"2025082410350821000_9.5.467.3","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2021-001374"},{"key":"2025082410350821000_9.5.467.4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(22)00519-1","article-title":"Thrombolysis for acute ischaemic stroke: Current status and future perspectives","volume":"22","author":"Tsivgoulis","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025082410350821000_9.5.467.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw550"},{"key":"2025082410350821000_9.5.467.6","first-page":"33","article-title":"Relationships between structure and function of tissue-type plasminogen activator","volume":"66","author":"Rijken","year":"1988","journal-title":"Klin Wochenschr"},{"key":"2025082410350821000_9.5.467.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80269-0"},{"key":"2025082410350821000_9.5.467.8","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179655"},{"key":"2025082410350821000_9.5.467.9","first-page":"632","article-title":"Properties of molecular variants of tissue-type plasminogen activator","volume":"39","author":"Krause","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"2025082410350821000_9.5.467.10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0025-7125(16)32431-2","article-title":"The physiology of Fibrinolysis","volume":"56","author":"Astrup","year":"1972","journal-title":"Med Clin North Am"},{"key":"2025082410350821000_9.5.467.11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cpt.33","article-title":"Recombinant tissue plasminogen Activators (rtPA): a review","volume":"97","author":"Gurman","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2025082410350821000_9.5.467.12","doi-asserted-by":"publisher","DOI":"10.1515\/bchm.1998.379.2.95"},{"key":"2025082410350821000_9.5.467.13","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/S0021-9258(19)81051-7","article-title":"Kinetics of the activation of plasminogen by human tissue plasminogen activator","volume":"257","author":"Hoylaerts","year":"1982","journal-title":"J Biol Chem"},{"key":"2025082410350821000_9.5.467.14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00018-019-03005-8","article-title":"The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe","volume":"76","author":"Zhu","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2025082410350821000_9.5.467.15","doi-asserted-by":"publisher","DOI":"10.1038\/301214a0"},{"key":"2025082410350821000_9.5.467.16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2007-1002675","article-title":"Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis","volume":"16","author":"Terashi","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"2025082410350821000_9.5.467.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332401"},{"key":"2025082410350821000_9.5.467.18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12795","article-title":"Alteplase or Tenecteplase for Thrombolysis in ischemic stroke: an illustrated review","volume":"6","author":"Zhu","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2025082410350821000_9.5.467.19","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/WNL.0000000000012781","article-title":"Global epidemiology of stroke and access to acute ischemic stroke interventions","volume":"97","author":"Saini","year":"2021","journal-title":"Neurology"},{"key":"2025082410350821000_9.5.467.20","article-title":"Rates of intravenous Thrombolysis and Endovascular therapy for acute ischaemic stroke in China between 2019 and 2020","volume":"21","author":"Ye","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2025082410350821000_9.5.467.21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/23969873211007684","article-title":"Stroke 20 20: implementation goals for intravenous Thrombolysis","volume":"6","author":"Mikulik","year":"2021","journal-title":"Eur Stroke J"},{"key":"2025082410350821000_9.5.467.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3670"},{"key":"2025082410350821000_9.5.467.23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bcp.2012.10.011","article-title":"Clot penetration and retention by plasminogen Activators promote Fibrinolysis","volume":"85","author":"Marcos-Contreras","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2025082410350821000_9.5.467.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07403-6"},{"key":"2025082410350821000_9.5.467.25","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.25.2805"},{"key":"2025082410350821000_9.5.467.26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.2.351"},{"key":"2025082410350821000_9.5.467.27","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241150-00001"},{"key":"2025082410350821000_9.5.467.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000154872.73240.e9"},{"key":"2025082410350821000_9.5.467.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30253-3"},{"key":"2025082410350821000_9.5.467.30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus Alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded Endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025082410350821000_9.5.467.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01054-6"},{"key":"2025082410350821000_9.5.467.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02600-9"},{"key":"2025082410350821000_9.5.467.33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11239-018-1721-3","article-title":"Tenecteplase versus Alteplase for management of acute ischemic stroke: a Pairwise and network meta-analysis of randomized clinical trials","volume":"46","author":"Kheiri","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2025082410350821000_9.5.467.34","doi-asserted-by":"crossref","DOI":"10.1038\/161559b0","article-title":"Staphylokinase; an activator of plasma protease","volume":"161","author":"LACK","year":"1948","journal-title":"Nature"},{"key":"2025082410350821000_9.5.467.35","doi-asserted-by":"publisher","DOI":"10.1007\/BF00330650"},{"key":"2025082410350821000_9.5.467.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00210-6"},{"key":"2025082410350821000_9.5.467.37","doi-asserted-by":"publisher","DOI":"10.1007\/BF00327208"},{"key":"2025082410350821000_9.5.467.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)45531-2"},{"key":"2025082410350821000_9.5.467.39","doi-asserted-by":"crossref","first-page":"11826","DOI":"10.1016\/S0021-9258(18)99031-9","article-title":"On the mechanism of fibrin-specific plasminogen activation by Staphylokinase","volume":"266","author":"Lijnen","year":"1991","journal-title":"J Biol Chem"},{"key":"2025082410350821000_9.5.467.40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.csbj.2019.06.023","article-title":"Structural biology and protein engineering of Thrombolytics","volume":"17","author":"Mican","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"2025082410350821000_9.5.467.41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V82.4.1175.1175","article-title":"Regulation by alpha 2-Antiplasmin and fibrin of the activation of plasminogen with recombinant Staphylokinase in plasma","volume":"82","author":"Silence","year":"1993","journal-title":"Blood"},{"key":"2025082410350821000_9.5.467.42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1055\/s-0038-1646440","article-title":"Comparative fibrinolytic properties of Staphylokinase and Streptokinase in animal models of venous thrombosis","volume":"66","author":"Lijnen","year":"1991","journal-title":"Thromb Haemost"},{"key":"2025082410350821000_9.5.467.43","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.3.996"},{"key":"2025082410350821000_9.5.467.44","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.6.1850"},{"key":"2025082410350821000_9.5.467.45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nbt0294-185","article-title":"High yield production and purification of recombinant Staphylokinase for thrombolytic therapy","volume":"12","author":"Schlott","year":"1994","journal-title":"Nat Biotechnol"},{"key":"2025082410350821000_9.5.467.46","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.8.2044"},{"key":"2025082410350821000_9.5.467.47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0038-1650619","article-title":"A pilot study on bolus administration of recombinant Staphylokinase for coronary artery Thrombolysis","volume":"76","author":"Vanderschueren","year":"1996","journal-title":"Thromb Haemost"},{"key":"2025082410350821000_9.5.467.48","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.2.197"},{"key":"2025082410350821000_9.5.467.49","unstructured":"Markin S , Semenov A , Markov V , et al . Clinical trial of Fibrinselective thrombolytic pharmaceutical agent \u00abFORTELYZIN\u00ae\u00bb(III phase). RUDN J Med 2012:105\u201310."},{"key":"2025082410350821000_9.5.467.50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41580-022-00568-6","article-title":"Regulation of adult stem cell quiescence and its functions in the maintenance of tissue integrity","volume":"24","author":"de Morree","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025082410350821000_9.5.467.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025082410350821000_9.5.467.52","doi-asserted-by":"crossref","DOI":"10.3390\/cells12232756","article-title":"The management of data for the banking, qualification, and distribution of induced Pluripotent stem cells: lessons learned from the European Bank for induced Pluripotent stem cells","volume":"12","author":"Mah","year":"2023","journal-title":"Cells"},{"key":"2025082410350821000_9.5.467.53","doi-asserted-by":"crossref","unstructured":"Ma C-Y , Zhai Y , Li CT , et al . Translating Mesenchymal stem cell and their Exosome research into GMP compliant advanced therapy products: promises, problems and prospects. Med Res Rev 2023. doi:10.1002\/med.22002","DOI":"10.1002\/med.22002"},{"key":"2025082410350821000_9.5.467.54","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009216"},{"key":"2025082410350821000_9.5.467.55","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41401-023-01061-2","article-title":"Angiogenesis after ischemic stroke","volume":"44","author":"Fang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"2025082410350821000_9.5.467.56","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2018-000199"},{"key":"2025082410350821000_9.5.467.57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ana.25493","article-title":"Cell therapy for ischemic stroke: are differences in Preclinical and clinical study design responsible for the Translational loss of efficacy","volume":"86","author":"Cui","year":"2019","journal-title":"Ann Neurol"},{"key":"2025082410350821000_9.5.467.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2017.03.003"},{"key":"2025082410350821000_9.5.467.59","unstructured":"Wang SN , CY M . Stem cell therapy in stroke: mechanism and progress in clinical research. Chin J Pharmacol Toxicol 2019:81\u201392."},{"key":"2025082410350821000_9.5.467.60","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.3390\/ijms21197380","article-title":"Clinical trials of stem cell therapy for cerebral ischemic stroke","volume":"21","author":"Kawabori","year":"2020","journal-title":"IJMS"},{"key":"2025082410350821000_9.5.467.61","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.018287"},{"key":"2025082410350821000_9.5.467.62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","article-title":"The secretion profile of Mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2025082410350821000_9.5.467.63","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/STROKEAHA.119.028072","article-title":"Bone marrow mononuclear cells activate angiogenesis via gap junction-mediated cell-cell interaction","volume":"51","author":"Kikuchi-Taura","year":"2020","journal-title":"Stroke"},{"key":"2025082410350821000_9.5.467.64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/neuros\/nyaa531","article-title":"Cell therapy for stroke: A mechanistic analysis","volume":"88","author":"Gu","year":"2021","journal-title":"Neurosurgery"},{"key":"2025082410350821000_9.5.467.65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000086518","article-title":"Neurotransplantation of fetal porcine cells in patients with basal ganglia Infarcts: a preliminary safety and feasibility study","volume":"20","author":"Savitz","year":"2005","journal-title":"Cerebrovasc Dis"},{"key":"2025082410350821000_9.5.467.66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13578-021-00698-y","article-title":"Allogeneic vs. Autologous Mesenchymal stem\/Stromal cells in their medication practice","volume":"11","author":"Li","year":"2021","journal-title":"Cell Biosci"},{"key":"2025082410350821000_9.5.467.67","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012701"},{"key":"2025082410350821000_9.5.467.68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(23)00005-4","article-title":"Intra-arterial bone marrow mononuclear cells for stroke","volume":"22","author":"Savitz","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025082410350821000_9.5.467.69","doi-asserted-by":"publisher","DOI":"10.3727\/096368910X494885"},{"key":"2025082410350821000_9.5.467.70","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00148","article-title":"Therapeutic plasticity of neural stem cells","volume":"11","author":"Ottoboni","year":"2020","journal-title":"Front Neurol"},{"key":"2025082410350821000_9.5.467.71","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.018290"},{"key":"2025082410350821000_9.5.467.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30513-X"},{"key":"2025082410350821000_9.5.467.73","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322515"},{"key":"2025082410350821000_9.5.467.74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2009.01050.x"},{"key":"2025082410350821000_9.5.467.75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2011.01260.x"},{"key":"2025082410350821000_9.5.467.76","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12975-019-00773-0","article-title":"Cerebral Organoids repair ischemic stroke brain injury","volume":"11","author":"Wang","year":"2020","journal-title":"Transl Stroke Res"},{"key":"2025082410350821000_9.5.467.77","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.601914"},{"key":"2025082410350821000_9.5.467.78","doi-asserted-by":"crossref","DOI":"10.1186\/scrt544","article-title":"The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow Mesenchymal stem cells in rats is related to cell dose and infusion velocity","volume":"6","author":"Cui","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"2025082410350821000_9.5.467.79","doi-asserted-by":"crossref","DOI":"10.3390\/cells11061013","article-title":"Mesenchymal Stromal cells in ischemic brain injury","volume":"11","author":"Brooks","year":"2022","journal-title":"Cells"},{"key":"2025082410350821000_9.5.467.80","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2010-18.2019"},{"key":"2025082410350821000_9.5.467.81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26867"},{"key":"2025082410350821000_9.5.467.82","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fneur.2019.00405","article-title":"World-wide efficacy of bone marrow derived Mesenchymal Stromal cells in Preclinical ischemic stroke models: systematic review and meta-analysis","volume":"10","author":"Satani","year":"2019","journal-title":"Front Neurol"},{"key":"2025082410350821000_9.5.467.83","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.81"},{"key":"2025082410350821000_9.5.467.84","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2174\/1570159X19666210806163352","article-title":"The role of stem cells in the therapy of stroke","volume":"20","author":"Ejma","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"2025082410350821000_9.5.467.85","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186718","article-title":"Recent advances in cell-based therapies for ischemic stroke","volume":"21","author":"Suda","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082410350821000_9.5.467.86","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112997","article-title":"Cell therapy of stroke: do the intra-arterially transplanted Mesenchymal stem cells cross the blood-brain barrier?","volume":"10","author":"Yarygin","year":"2021","journal-title":"Cells"},{"key":"2025082410350821000_9.5.467.87","doi-asserted-by":"crossref","first-page":"105458","DOI":"10.1016\/j.neuint.2022.105458","article-title":"Stroke: molecular mechanisms and therapies: update on recent developments","volume":"162","author":"Shehjar","year":"2023","journal-title":"Neurochem Int"},{"key":"2025082410350821000_9.5.467.88","doi-asserted-by":"publisher","DOI":"10.1038\/nature12517"},{"key":"2025082410350821000_9.5.467.89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41401-022-00986-4","article-title":"Humanized cerebral Organoids-based ischemic stroke model for discovering of potential anti-stroke agents","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"2025082410350821000_9.5.467.90","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/cns.12754","article-title":"Organoid technology for brain and Therapeutics research","volume":"23","author":"Wang","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"2025082410350821000_9.5.467.91","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/cns.13286","article-title":"Cerebral Organoids transplantation improves neurological motor function in rat brain injury","volume":"26","author":"Wang","year":"2020","journal-title":"CNS Neurosci Ther"},{"key":"2025082410350821000_9.5.467.92","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4103\/1673-5374.369100","article-title":"The generation and properties of human cortical Organoids as a disease model for malformations of cortical development","volume":"18","author":"Zhang","year":"2023","journal-title":"Neural Regen Res"},{"key":"2025082410350821000_9.5.467.93","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4127"},{"key":"2025082410350821000_9.5.467.94","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0219-18.2018","article-title":"Vascularization and Engraftment of transplanted human cerebral Organoids in Mouse cortex","volume":"5","author":"Daviaud","year":"2018","journal-title":"eNeuro"},{"key":"2025082410350821000_9.5.467.95","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41380-020-00910-4","article-title":"Human cerebral Organoids establish subcortical projections in the Mouse brain after transplantation","volume":"26","author":"Dong","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2025082410350821000_9.5.467.96","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35536-3","article-title":"Multimodal monitoring of human cortical Organoids implanted in mice reveal functional connection with visual cortex","volume":"13","author":"Wilson","year":"2022","journal-title":"Nat Commun"},{"key":"2025082410350821000_9.5.467.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.01.004"},{"key":"2025082410350821000_9.5.467.98","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human Prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: A phase 3 randomized clinical trial","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025082410350821000_9.5.467.99","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.023927"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2023-002883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:35:30Z","timestamp":1756056930000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2023-002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":99,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,5]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/svn-2023-002883"],"URL":"https:\/\/doi.org\/10.1136\/svn-2023-002883","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}